Curis, Inc.

Introduction

This page provides a comprehensive analysis of the known insider trading history of James R Tobin. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate James R Tobin has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:TMDX / TransMedics Group, Inc. Director 4,059
US:GMED / Globus Medical, Inc. Director 21,458
US:LYRA / Lyra Therapeutics, Inc. Director 14,500
Director 0
US:CVRS / Corindus Vascular Robotics, Inc. Director 0
Director 10,000
US:CRIS / Curis, Inc. Director 25,000
US:BSX / Boston Scientific Corporation President & CEO, Director 2,000,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by James R Tobin. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases CRIS / Curis, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CRIS / Curis, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CRIS / Curis, Inc. Insider Trades
Insider Sales CRIS / Curis, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CRIS / Curis, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CRIS / Curis, Inc. Insider Trades
Insider Purchases LYRA / Lyra Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CRIS / Curis, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LYRA / Lyra Therapeutics, Inc. Insider Trades
Insider Sales LYRA / Lyra Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CRIS / Curis, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LYRA / Lyra Therapeutics, Inc. Insider Trades
Insider Purchases TMDX / TransMedics Group, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CRIS / Curis, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TMDX / TransMedics Group, Inc. Insider Trades
Insider Sales TMDX / TransMedics Group, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CRIS / Curis, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2024-08-08 TMDX TOBIN JAMES R 12,664 158.9600 12,664 158.9600 2,013,069 166 56.7300 -1,294,640 -64.31
2024-08-08 TMDX TOBIN JAMES R 7,336 159.9600 7,336 159.9600 1,173,467
2023-11-28 TMDX TOBIN JAMES R 10,000 70.1400 10,000 70.1400 701,400

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TMDX / TransMedics Group, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by James R Tobin as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-05-23 2025-05-22 4 TMDX TransMedics Group, Inc.
Common Stock
A - Award 2,134 4,059 110.86
2024-09-17 2024-09-13 4 TMDX TransMedics Group, Inc.
Common Stock
G - Gift 18,000 18,000
2024-09-17 2024-09-13 4 TMDX TransMedics Group, Inc.
Common Stock
G - Gift -18,000 155,146 -10.40
2024-08-09 2024-08-08 4 TMDX TransMedics Group, Inc.
Common Stock
S - Sale -7,336 173,146 -4.06 159.96 -1,173,467 27,696,434
2024-08-09 2024-08-08 4 TMDX TransMedics Group, Inc.
Common Stock
S - Sale -12,664 180,482 -6.56 158.96 -2,013,069 28,689,419
2024-05-28 2024-05-23 4 TMDX TransMedics Group, Inc.
Common Stock
A - Award 732 1,925 61.36
2024-05-07 2024-05-03 4 TMDX TransMedics Group, Inc.
Common Stock
S - Sale X -6,895 193,146 -3.45 125.26 -863,668 24,193,468
2024-05-07 2024-05-03 4 TMDX TransMedics Group, Inc.
Common Stock
S - Sale X -5,130 200,041 -2.50 124.76 -640,019 24,957,115
2024-05-03 2024-05-01 4 TMDX TransMedics Group, Inc.
Common Stock
S - Sale X -2,000 205,171 -0.97 110.00 -220,000 22,568,810
2024-05-03 2024-05-01 4 TMDX TransMedics Group, Inc.
Common Stock
S - Sale X -100 207,171 -0.05 108.47 -10,847 22,471,838
2024-05-03 2024-05-01 4 TMDX TransMedics Group, Inc.
Common Stock
S - Sale X -1,704 207,271 -0.82 106.89 -182,141 22,155,197
2024-05-03 2024-05-01 4 TMDX TransMedics Group, Inc.
Common Stock
S - Sale X -11,236 208,975 -5.10 105.70 -1,187,645 22,088,658
2024-03-05 2024-03-01 4 TMDX TransMedics Group, Inc.
Common Stock
S - Sale X -300 220,211 -0.14 85.48 -25,644 18,823,636
2024-03-05 2024-03-01 4 TMDX TransMedics Group, Inc.
Common Stock
S - Sale X -2,900 220,511 -1.30 84.74 -245,746 18,686,102
2024-03-05 2024-03-01 4 TMDX TransMedics Group, Inc.
Common Stock
S - Sale X -5,746 223,411 -2.51 83.63 -480,538 18,683,862
2024-03-05 2024-03-01 4 TMDX TransMedics Group, Inc.
Common Stock
S - Sale X -4,234 229,157 -1.81 82.84 -350,745 18,983,366
2024-03-05 2024-03-01 4 TMDX TransMedics Group, Inc.
Common Stock
S - Sale X -200 233,391 -0.09 81.41 -16,282 19,000,361
2023-11-29 2023-11-28 4 TMDX TransMedics Group, Inc.
Common Stock
S - Sale -10,000 233,591 -4.11 70.14 -701,400 16,384,073
2023-05-30 2023-05-25 4 TMDX TransMedics Group, Inc.
Common Stock
A - Award 1,193 1,193
2023-02-27 2023-02-23 4 TMDX TransMedics Group, Inc.
Common Stock
S - Sale X -10,000 243,591 -3.94 75.13 -751,300 18,300,992
2022-08-01 2022-07-29 4 TMDX TransMedics Group, Inc.
Common Stock
S - Sale X -48,515 253,591 -16.06 39.98 -1,939,630 10,138,568
2022-07-06 2022-07-05 4 TMDX TransMedics Group, Inc.
Common Stock
S - Sale X -48,515 302,106 -13.84 35.00 -1,698,025 10,573,710
2022-05-06 2022-05-04 4 TMDX TransMedics Group, Inc.
Common Stock
S - Sale X -48,516 350,621 -12.16 29.94 -1,452,569 10,497,593
2022-03-17 2022-03-15 4 GMED GLOBUS MEDICAL INC
Stock Option (Right to Buy Class A Common Stock)
M - Exercise -3,542 21,458 -14.17
2022-03-17 2022-03-15 4 GMED GLOBUS MEDICAL INC
Stock Option (Right to Buy Class A Common Stock)
M - Exercise -5,308 5,208 -50.48
2022-03-17 2022-03-15 4 GMED GLOBUS MEDICAL INC
Class A Common Stock
S - Sale -8,850 0 -100.00 65.47 -579,418
2022-03-17 2022-03-15 4 GMED GLOBUS MEDICAL INC
Class A Common Stock
M - Exercise 3,542 8,850 66.73 53.27 188,682 471,440
2022-03-17 2022-03-15 4 GMED GLOBUS MEDICAL INC
Class A Common Stock
M - Exercise 5,308 5,308 43.58 231,323 231,323
2022-03-10 2022-03-10 4 GMED GLOBUS MEDICAL INC
Stock Option (Right to Buy Class A Common Stock)
M - Exercise -10,000 10,516 -48.74
2022-03-10 2022-03-10 4 GMED GLOBUS MEDICAL INC
Class A Common Stock
S - Sale -10,000 0 -100.00 70.04 -700,398
2022-03-10 2022-03-10 4 GMED GLOBUS MEDICAL INC
Class A Common Stock
M - Exercise 10,000 10,000 43.58 435,800 435,800
2022-03-10 2022-03-08 4 GMED GLOBUS MEDICAL INC
Stock Option (Right to Buy Class A Common Stock)
M - Exercise -4,484 20,516 -17.94
2022-03-10 2022-03-08 4 GMED GLOBUS MEDICAL INC
Class A Common Stock
S - Sale -4,484 0 -100.00 72.00 -322,848
2022-03-10 2022-03-08 4 GMED GLOBUS MEDICAL INC
Class A Common Stock
M - Exercise 4,484 4,484 43.58 195,413 195,413
2022-03-08 2022-03-04 4 LYRA Lyra Therapeutics, Inc.
Stock Option
A - Award 14,500 14,500
2022-01-31 2022-01-27 4 GMED GLOBUS MEDICAL INC
Stock Option (Right to Buy Class A Common Stock)
A - Award 15,000 15,000
2021-12-16 2021-12-15 4 TMDX TransMedics Group, Inc.
Common Stock
G - Gift -25,500 399,137 -6.01
2021-06-01 2021-05-27 4 TMDX TransMedics Group, Inc.
Stock Option (Right to Buy)
A - Award 13,500 13,500
2021-05-12 2021-05-10 4 GMED GLOBUS MEDICAL INC
Stock Option (Right to Buy Class A Common Stock)
M - Exercise -25,000 0 -100.00
2021-05-12 2021-05-10 4 GMED GLOBUS MEDICAL INC
Class A Common Stock
S - Sale -25,000 0 -100.00 71.96 -1,799,000
2021-05-12 2021-05-10 4 GMED GLOBUS MEDICAL INC
Class A Common Stock
M - Exercise 25,000 25,000 43.77 1,094,250 1,094,250
2021-03-12 2021-03-08 4 OXFD Oxford Immunotec Global PLC
Stock Option (Right to Buy)
D - Sale to Issuer -9,494 0 -100.00 9.04 -85,826
2021-03-12 2021-03-08 4 OXFD Oxford Immunotec Global PLC
Stock Option (Right to Buy)
D - Sale to Issuer -7,457 0 -100.00 7.83 -58,388
2021-03-12 2021-03-08 4 OXFD Oxford Immunotec Global PLC
Stock Option (Right to Buy)
D - Sale to Issuer -7,457 0 -100.00 8.98 -66,964
2021-03-12 2021-03-08 4 OXFD Oxford Immunotec Global PLC
Stock Option (Right to Buy)
D - Sale to Issuer -14,914 0 -100.00 8.98 -133,928
2021-03-12 2021-03-08 4 OXFD Oxford Immunotec Global PLC
Stock Option (Right to Buy)
D - Sale to Issuer -7,457 0 -100.00 7.56 -56,375
2021-03-12 2021-03-08 4 OXFD Oxford Immunotec Global PLC
Stock Option (Right to Buy)
D - Sale to Issuer -7,457 0 -100.00 7.51 -56,002
2021-03-12 2021-03-08 4 OXFD Oxford Immunotec Global PLC
Stock Option (Right to Buy)
D - Sale to Issuer -7,457 0 -100.00 7.54 -56,226
2021-03-12 2021-03-08 4 OXFD Oxford Immunotec Global PLC
Stock Option (Right to Buy)
D - Sale to Issuer -7,457 0 -100.00 13.35 -99,551
2021-03-12 2021-03-08 4 OXFD Oxford Immunotec Global PLC
Ordinary Shares
D - Sale to Issuer -4,081 0 -100.00 22.00 -89,782
2021-02-10 2021-02-09 4 TMDX TransMedics Group, Inc.
Common Stock
S - Sale X -200 424,637 -0.05 34.18 -6,836 14,514,093
2021-02-10 2021-02-09 4 TMDX TransMedics Group, Inc.
Common Stock
S - Sale X -9,968 424,837 -2.29 32.80 -326,950 13,934,654
2021-01-19 2021-01-14 4 GMED GLOBUS MEDICAL INC
Stock Option (Right to Buy Class A Common Stock)
A - Award 15,000 15,000
2020-09-03 2020-09-02 4 GMED GLOBUS MEDICAL INC
Stock Option (Right to Buy Class A Common Stock)
M - Exercise -5,600 0 -100.00
2020-09-03 2020-09-02 4 GMED GLOBUS MEDICAL INC
Class A Common Stock
S - Sale -5,600 0 -100.00 56.85 -318,360
2020-09-03 2020-09-02 4 GMED GLOBUS MEDICAL INC
Class A Common Stock
M - Exercise 5,600 5,600 26.27 147,112 147,112
2020-08-26 2020-08-25 4 GMED GLOBUS MEDICAL INC
Stock Option (Right to Buy Class A Common Stock)
M - Exercise -17,400 5,600 -75.65
2020-08-26 2020-08-25 4 GMED GLOBUS MEDICAL INC
Class A Common Stock
S - Sale -17,400 0 -100.00 54.40 -946,560
2020-08-26 2020-08-25 4 GMED GLOBUS MEDICAL INC
Class A Common Stock
M - Exercise 17,400 17,400 26.27 457,098 457,098
2020-06-26 2020-06-24 4 OXFD Oxford Immunotec Global PLC
Share Option (Right to Buy)
A - Award 9,494 9,494
2020-06-26 2020-06-24 4 OXFD Oxford Immunotec Global PLC
Ordinary Shares
A - Award 4,081 4,081
2020-06-05 2020-06-04 4 TMDX TransMedics Group, Inc.
Stock Option (Right to Buy)
A - Award 15,934 15,934
2020-01-24 2020-01-22 4 GMED GLOBUS MEDICAL INC
Stock Option (Right to Buy Class A Common Stock)
A - Award 25,000 25,000
2019-10-31 2019-10-29 4 CVRS Corindus Vascular Robotics, Inc.
Common Stock
D - Sale to Issuer -106,112 0 -100.00 4.28 -454,159
2019-10-09 2019-10-07 4 CVRS Corindus Vascular Robotics, Inc.
Common Stock
A - Award 1,170 106,112 1.11 4.27 4,996 453,098
2019-07-10 2019-07-08 4 CVRS Corindus Vascular Robotics, Inc.
Common Stock
A - Award 1,453 104,942 1.40 3.44 4,998 361,000
2019-06-19 2019-06-18 4 OXFD Oxford Immunotec Global PLC
SHARE OPTION (RIGHT TO BUY)
A - Award 7,457 7,457
2019-05-07 2019-05-03 4 CVRS Corindus Vascular Robotics, Inc.
Common Stock
A - Award 27,649 103,489 36.46 2.17 59,998 224,571
2019-05-06 2019-05-06 4 TMDX TransMedics Group, Inc.
Series F Convertible Preferred Stock
C - Conversion -221,820 0 -100.00
2019-05-06 2019-05-06 4 TMDX TransMedics Group, Inc.
Series C Convertible Preferred Stock
C - Conversion -400,000 0 -100.00
2019-05-06 2019-05-06 4 TMDX TransMedics Group, Inc.
Series D Convertible Preferred Stock
C - Conversion -400,000 0 -100.00
2019-05-06 2019-05-06 4 TMDX TransMedics Group, Inc.
Common Stock
C - Conversion 291,948 434,805 204.36
2019-05-06 2019-05-06 4 TMDX TransMedics Group, Inc.
Common Stock
J - Other 142,857 142,857
2019-05-06 2019-05-06 4 TMDX TransMedics Group, Inc.
Common Stock
J - Other -500,000 0 -100.00
2019-05-01 3 TMDX TransMedics Group, Inc.
Common Stock
285,714
2019-05-01 3 TMDX TransMedics Group, Inc.
Common Stock
285,714
2019-05-01 3 TMDX TransMedics Group, Inc.
Common Stock
285,714
2019-04-09 2019-04-05 4 CVRS Corindus Vascular Robotics, Inc.
Common Stock
A - Award 2,358 75,840 3.21 2.12 4,999 160,781
2019-02-28 2019-02-28 4 GMED GLOBUS MEDICAL INC
Stock Option (Right to Buy Class A Common Stock)
M - Exercise -2,000 23,000 -8.00
2019-02-28 2019-02-28 4 GMED GLOBUS MEDICAL INC
Stock Option (Right to Buy Class A Common Stock)
M - Exercise -20,000 0 -100.00
2019-02-28 2019-02-28 4 GMED GLOBUS MEDICAL INC
Stock Option (Right to Buy Class A Common Stock)
M - Exercise -6,100 0 -100.00
2019-02-28 2019-02-28 4 GMED GLOBUS MEDICAL INC
Class A Common Stock
S - Sale -9,300 0 -100.00 47.04 -437,472
2019-02-28 2019-02-28 4 GMED GLOBUS MEDICAL INC
Class A Common Stock
S - Sale -18,800 9,300 -66.90 48.10 -904,280 447,330
2019-02-28 2019-02-28 4 GMED GLOBUS MEDICAL INC
Class A Common Stock
M - Exercise 2,000 28,100 7.66 26.27 52,540 738,187
2019-02-28 2019-02-28 4 GMED GLOBUS MEDICAL INC
Class A Common Stock
M - Exercise 20,000 26,100 327.87 25.52 510,400 666,072
2019-02-28 2019-02-28 4 GMED GLOBUS MEDICAL INC
Class A Common Stock
M - Exercise 6,100 6,100 24.75 150,975 150,975
2019-02-28 2019-02-26 4 GMED GLOBUS MEDICAL INC
Stock Option (Right to Buy Class A Common Stock)
M - Exercise -8,900 6,100 -59.33
2019-02-28 2019-02-26 4 GMED GLOBUS MEDICAL INC
Class A Common Stock
S - Sale -400 0 -100.00 47.91 -19,164
2019-02-28 2019-02-26 4 GMED GLOBUS MEDICAL INC
Class A Common Stock
S - Sale -8,500 400 -95.51 47.06 -400,010 18,824
2019-02-28 2019-02-26 4 GMED GLOBUS MEDICAL INC
Class A Common Stock
M - Exercise 8,900 8,900 24.75 220,275 220,275
2019-02-11 2019-01-22 4 GMED GLOBUS MEDICAL INC
Stock Option (Right to Buy Class A Common Stock)
A - Award 25,000 25,000
2019-01-10 2019-01-08 4 CVRS Corindus Vascular Robotics, Inc.
Common Stock
A - Award 4,464 73,482 6.47 1.12 5,000 82,300
2018-10-09 2018-10-05 4 CVRS Corindus Vascular Robotics, Inc.
Common Stock
A - Award 3,200 69,018 4.86 1.25 4,000 86,272
2018-07-11 2018-07-09 4 CVRS Corindus Vascular Robotics, Inc.
Common Stock
A - Award 4,273 65,818 6.94 1.17 4,999 77,007
2018-06-21 2018-06-19 4 OXFD Oxford Immunotec Global PLC
SHARE OPTION (RIGHT TO BUY)
A - Award 7,457 7,457
2018-06-04 2018-05-31 4 CVRS Corindus Vascular Robotics, Inc.
Common Stock
A - Award 53,326 61,545 648.81 0.75 40,000 46,165
2018-03-15 2018-03-13 4 CVRS Corindus Vascular Robotics, Inc.
Common Stock
A - Award 8,219 8,219
2018-01-24 2018-01-22 4 GMED GLOBUS MEDICAL INC
Stock Option (Right to Buy Class A Common Stock)
A - Award 25,000 25,000
2017-06-08 2017-06-06 4 OXFD Oxford Immunotec Global PLC
SHARE OPTION (RIGHT TO BUY)
A - Award 7,457 7,457
2017-02-01 2017-01-30 4 GMED GLOBUS MEDICAL INC
Stock Option (Right to Buy Class A Common Stock)
A - Award 25,000 25,000
2016-06-29 2016-06-28 4 OXFD Oxford Immunotec Global PLC
SHARE OPTION (RIGHT TO BUY)
A - Award 7,457 7,457
2016-06-13 2016-06-09 4 CHMA CHIASMA, INC
Stock Option (Right to Buy)
A - Award 10,000 10,000
2016-01-27 2016-01-25 4 GMED GLOBUS MEDICAL INC
Stock Option (Right to Buy Class A Common Stock)
A - Award 20,000 20,000
2015-12-11 2015-12-10 4 CHMA CHIASMA, INC
Stock Option (right to buy)
A - Award 20,000 20,000
2015-09-01 2015-08-28 4 GMED GLOBUS MEDICAL INC
Stock Option (Right to Buy Class A Common Stock)
A - Award 15,000 15,000
2015-09-01 3 GMED GLOBUS MEDICAL INC
No securities beneficially owned
0
2015-06-12 2015-06-09 4 OXFD Oxford Immunotec Global PLC
SHARE OPTION (RIGHT TO BUY)
A - Award 7,457 7,457
2015-01-28 2015-01-26 4 CRIS CURIS INC
Non-qualified stock option (right to buy)
A - Award 25,000 25,000
2014-12-05 2014-12-01 4 OXFD Oxford Immunotec Global PLC
SHARE OPTION (RIGHT TO BUY)
A - Award 14,914 14,914
2014-12-05 2014-12-01 4 OXFD Oxford Immunotec Global PLC
SHARE OPTION (RIGHT TO BUY)
A - Award 7,457 7,457
2014-01-28 2014-01-27 4 CRIS CURIS INC
Non-qualified stock option (right to buy)
A - Award 25,000 25,000
2013-05-07 2013-05-06 4 CRIS CURIS INC
Non-qualified stock option
M - Exercise -62,500 0 -100.00
2013-05-07 2013-05-06 4 CRIS CURIS INC
Common stock
F - Taxes -41,830 144,921 -22.40 3.63 -151,843 526,063
2013-05-07 2013-05-06 4 CRIS CURIS INC
Common stock
M - Exercise 62,500 186,751 50.30 2.43 151,875 453,805
2013-01-18 2013-01-17 4 CRIS CURIS INC
Non-qualified stock option (right to buy)
A - Award 25,000 25,000
2012-03-09 2012-03-08 4 CRIS CURIS INC
Non-qualified stock option
M - Exercise -2,500 0 -100.00 1.09 -2,725
2012-03-09 2012-03-08 4 CRIS CURIS INC
Non-qualified stock option
M - Exercise -75,000 0 -100.00 1.50 -112,500
2012-03-09 2012-03-08 4 CRIS CURIS INC
Common stock
M - Exercise 2,500 124,251 2.05 1.09 2,725 135,434
2012-03-09 2012-03-08 4 CRIS CURIS INC
Common stock
M - Exercise 75,000 121,751 160.42 1.50 112,500 182,626
2012-01-06 2012-01-05 4 CRIS CURIS INC
Non-qualified stock option (right to buy)
A - Award 50,000 25,000 -200.00
2009-02-26 2009-02-24 4 BSX BOSTON SCIENTIFIC CORP
Stock Option (Right to Buy)
A - Award 2,000,000 2,000,000
2005-06-03 2005-06-01 4 CRIS CURIS INC
Non-qualified stock option (right to buy)
A - Award 5,000 5,000 3.98 19,900 19,900
2005-06-03 2005-06-01 4 CRIS CURIS INC
Non-qualified stock option (right to buy)
A - Award 5,000 5,000 3.98 19,900 19,900
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)